Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Receivables (2022 - 2025)

ProQR Therapeutics' Receivables history spans 3 years, with the latest figure at $8.3 million for Q4 2025.

  • On a quarterly basis, Receivables rose 69.1% to $8.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.3 million, a 69.1% increase, with the full-year FY2025 number at $8.3 million, up 69.1% from a year prior.
  • Receivables hit $8.3 million in Q4 2025 for ProQR Therapeutics, up from $4.9 million in the prior quarter.
  • Over the last five years, Receivables for PRQR hit a ceiling of $57.8 million in Q4 2022 and a floor of $4.9 million in Q4 2024.
  • Historically, Receivables has averaged $23.7 million across 3 years, with a median of $8.3 million in 2025.
  • The widest YoY moves for Receivables: up 69.1% in 2025, down 69.1% in 2025.
  • Tracing PRQR's Receivables over 3 years: stood at $57.8 million in 2022, then plummeted by 91.53% to $4.9 million in 2024, then soared by 69.1% to $8.3 million in 2025.
  • Business Quant data shows Receivables for PRQR at $8.3 million in Q4 2025, $4.9 million in Q4 2024, and $57.8 million in Q4 2022.